Patients (n, %) | 714 | 100 |
Male (n, %) | 345 | 48.3 |
Female (n, %) | 369 | 51.7 |
Age, years (median, IQR) | 35 | 30 - 42 |
Clinical stage | ||
CDC A (n, %) | 354 | 49.6 |
CDC B (n, %) | 158 | 22.1 |
CDC C (n, %) | 202 | 28.3 |
CD4+ T cell count, cells/μL (median, IQR) | 350 | 220 - 533 |
CD4+ T cells, percent (median, IQR) | 21.0 | 15.0 - 29.0 |
CD8+ T cell count, cells/μL (median, IQR) | 808 | 565 - 1133 |
CD8+ T cells, percent (median, IQR) | 51.0 | 41.0 - 59.0 |
Patients with HIV-1 RNA <50 copies/mL (n, %) | 308 | 43.1 |
Patients with HIV-1 RNA ≥50 copies/mL (n, %) | 406 | 56.9 |
HIV-1 RNA among these (log [copies/mL], IQR) | 3.94 | 2.97-4.68 |
HIV-1 clade (n, %) | ||
B | 94 | 13.2 |
Non-B (15 different clades) | 620 | 86.8 |
Treatment status | ||
HAART-naive (n, %) | 190 | 26.6 |
Receiving HAART (n, %) | 524 | 73.4 |
Months on HAART if receiving HAART (median, IQR) | 13.5 | 11.1 - 17.8 |